C

B

COUDERT , Benoit

Last name: COUDERT

First name: Benoit

November 2020 (v1)

Journal article

Metadata-only

Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study

Coudert, Benoit Pierga, Jean-Yves Mouret-Reynier, Marie-Ange

Background: The open-label, randomised Phase 2 AVATAXHER study (NCT01142778) demonstrated that early PET assessment identified HER2-positive breast cancer patients who responded poorly to neoadjuvant docetaxel plus trastuzumab. Adding neoadjuvant bevacizumab for PET-predicted poor-responders improved pathological complete response (pCR) rates...

Uploaded on: December 4, 2022